Cepheid 's CPHD rapid influenza and RSV assay - the Xpert Flu+RSV Xpress test - recently won the U.S. FDA 510(k) marketing approval and the Clinical Laboratory Improvement Achievements (CLIA) waiver.

The World Health Organization (WHO) gave its backing on Wednesday to a new molecular test for tuberculosis made by Cepheid which can rapidly diagnose TB, one of the world's biggest killer diseases.

SUNNYVALE, Calif., June 9, 2020 /PRNewswire/ -- Cepheid today announced the development of a next-generation test to assist global efforts in the fight against the spread of COVID-19 during the ...

SUNNYVALE, Calif. , Feb. 18, 2026 /PRNewswire/ -- Cepheid today announced that it has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators ...

Managing One of the Largest Enterovirus Testing Populations, Children's Medical Center Dallas Among Leading Institutions to Quickly Adopt Cepheid's SUNNYVALE, Calif ...

Just in time for peak flu season, Cepheid ($CPHD) got an FDA nod for its rapid influenza and RSV test for doctors' offices, giving the company some added momentum as ...

Cepheid is developing a rapid test, known as Xpert Carba-R, for detecting multidrug-resistant pathogens. The test has several advantages over existing diagnostic methods. The company successfully ...

As controversy rises over equal access to Covid-19 medical products, a manufacturer of rapid, point-of care tests is being urged to lower the price of its diagnostic and also increase sales to a World ...

Cepheid ($CPHD) scored an FDA OK to market its next-generation in vitro test for norovirus, helping the company generate some upward momentum as it ramps up its ...

Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here. The Food and Drug Administration (FDA) issued emergency authorization Saturday for a novel coronavirus ...